Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-medetomidine infusion in pediatric open heart surgery
IRCT2016061927617N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine in Cardiovascular Malformation (CVM), Ventricular Septal Defect (VSD), Congenital pulmonary valve abnormality and 3 more, sponsored by Iran University of Medical Sciences. Primary endpoints: Pro-inflammatory cytokines and Anti-inflammatory cytokines. Started Jul 2016; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
Cardiovascular Malformation (CVM)Ventricular Septal Defect (VSD)Congenital pulmonary valve abnormalitycongenital tricuspid valve diseasecongenital aortic valve malformation
Beyond the preview
Go deeper on IRCT2016061927617N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016061927617N2.